Yunnan Baiyao Group Co.,Ltd

SZSE:000538 Stock Report

Market Cap: CN¥102.5b

Yunnan Baiyao GroupLtd Past Earnings Performance

Past criteria checks 1/6

Yunnan Baiyao GroupLtd's earnings have been declining at an average annual rate of -1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.8% per year. Yunnan Baiyao GroupLtd's return on equity is 10.7%, and it has net margins of 10.9%.

Key information

-1.0%

Earnings growth rate

-0.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.8%
Return on equity10.7%
Net Margin10.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Calculating The Fair Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)

Oct 03
Calculating The Fair Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)

Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Business And Shares Still Trailing The Market

Sep 15
Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Business And Shares Still Trailing The Market

Yunnan Baiyao GroupLtd (SZSE:000538) Could Easily Take On More Debt

Aug 06
Yunnan Baiyao GroupLtd (SZSE:000538) Could Easily Take On More Debt

A Look At The Intrinsic Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)

Jun 30
A Look At The Intrinsic Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)

Earnings Working Against Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Share Price

Apr 21
Earnings Working Against Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Share Price

Yunnan Baiyao Group Co.,Ltd Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next

Apr 02
Yunnan Baiyao Group Co.,Ltd Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next

Yunnan Baiyao Group Co.,Ltd (SZSE:000538) Shares Could Be 34% Above Their Intrinsic Value Estimate

Feb 27
Yunnan Baiyao Group Co.,Ltd (SZSE:000538) Shares Could Be 34% Above Their Intrinsic Value Estimate

Revenue & Expenses Breakdown

How Yunnan Baiyao GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:000538 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2439,3384,2976,157334
30 Jun 2439,2574,4556,272339
31 Mar 2439,3734,2786,323329
31 Dec 2339,1114,0946,230336
30 Sep 2339,2614,8204,858347
30 Jun 2338,7814,3295,363353
31 Mar 2337,5723,6055,353348
01 Jan 2336,4883,0015,186337
30 Sep 2234,9272,6595,467344
30 Jun 2235,3082,5044,694354
31 Mar 2235,4762,9565,202331
01 Jan 2236,3742,8055,194331
30 Sep 2137,1743,7145,647250
30 Jun 2136,3324,8645,582203
31 Mar 2135,3274,9975,110189
31 Dec 2032,7435,5164,754181
30 Sep 2031,9504,8954,850193
30 Jun 2031,2614,3905,018193
31 Mar 2030,4023,5095,067191
31 Dec 1929,6654,1845,134174
30 Sep 1928,6863,7404,321141
30 Jun 1927,7693,6714,159124
31 Mar 1927,6854,6443,965114
01 Jan 1927,0173,4943,988112
30 Sep 1826,2843,8364,498102
30 Jun 1825,4993,6494,119137
31 Mar 1824,7433,2264,057111
31 Dec 1724,3153,1454,01584
30 Sep 1724,1313,1653,59061
30 Jun 1723,9193,0973,7580
31 Mar 1723,1493,0233,5060
31 Dec 1622,4112,9203,2910
30 Sep 1622,3382,9893,3810
30 Jun 1621,6482,9043,2560
31 Mar 1621,2002,8313,2170
31 Dec 1520,7382,7713,1720
30 Sep 1520,1852,7043,1010
30 Jun 1519,7302,6312,9780
31 Mar 1519,3642,5642,8060
31 Dec 1418,8142,5062,7770
30 Sep 1417,9042,5072,6300
30 Jun 1417,1312,5152,7620
31 Mar 1416,6252,4502,7650
31 Dec 1315,8152,3212,6170

Quality Earnings: 000538 has high quality earnings.

Growing Profit Margin: 000538's current net profit margins (10.9%) are lower than last year (12.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 000538's earnings have declined by 1% per year over the past 5 years.

Accelerating Growth: 000538's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000538 had negative earnings growth (-10.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


Return on Equity

High ROE: 000538's Return on Equity (10.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies